Tryptophan metabolism and its relationship with immune activation, depression, and neurocognitive impairment among HIV-infected individuals by Keegan, MR et al.
UC San Diego
UC San Diego Previously Published Works
Title
Tryptophan metabolism and its relationship with immune activation, depression, and 
neurocognitive impairment among HIV-infected individuals
Permalink
https://escholarship.org/uc/item/0qc3k0m1
Authors
Keegan, MR
Chittiprol, S
Winston, A
et al.
Publication Date
2013
DOI
10.4137/IJTR.S36464
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
79InternatIonal Journal of tryptophan research 2016:9
Introduction
HIV-1 enters the central nervous system (CNS) during the early 
stages of HIV infection1 and has been associated with neuro-
logical and neuropsychiatric effects, including major depres-
sive disorder (MDD) and cognitive impairment (CI). The 
reported rates of MDD in people living with HIV (PLWH) 
vary from 5% to almost 50%.2 The relationship between HIV 
infection and MDD is complex with several factors likely 
contributing to its development and persistence.3–8 Untreated 
depression in PLWH is associated with nonadhe rence to anti-
retroviral therapy (ART),9 more rapid progression to AIDS,10 
and shorter survival.11
CI is highly prevalent among HIV-positive (HIV+) 
individuals. Following the advent of effective ART, the 
incidence of the most severe forms of HIV-related CI has 
decreased dramatically. In contrast, the prevalence rates of less 
severe forms remains high,12–16 although in recent studies of 
patients well maintained on ART, rates are lower.17
Despite being of a milder form, HIV-related CI affects 
daily function, ART adherence, and quality of life.18,19
HIV-related CNS disease is characterized by neuronal 
loss, reactive astrogliosis, activated microglia, and leuko-
cyte infiltration. HIV-infected cells in the CNS include 
perivascular macrophages and microglia, but not neurons, 
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AbstrAct
ObjectIve: Cognitive impairment (CI) and major depressive disorder (MDD) remain prevalent in treated HIV-1 disease; however, the pathogenesis 
remains elusive. A possible contributing mechanism is immune-mediated degradation of tryptophan (TRP) via the kynurenine (KYN) pathway, resulting 
in decreased production of serotonin and accumulation of TRP degradation products. We explored the association of these biochemical pathways and their 
relationship with CI and MDD in HIV-positive (HIV+) individuals.
MethOds: In a cross-sectional analysis, concentrations of neopterin (NEO), tumor necrosis factor-alpha, TRP, KYN, KYN/TRP ratio, phenylalanine 
(PHE), tyrosine (TYR), PHE/TYR ratio, and nitrite were assessed in the cerebrospinal fluid (CSF) and plasma of HIV+ (n = 91) and HIV-negative (HIV−) 
individuals (n = 66). CI and MDD were assessed via a comprehensive neuropsychological test battery. A Global Deficit Score $0.5 was defined as CI. 
Nonparametric statistical analyses included Kruskal–Wallis and Mann–Whitney U tests, and multivariate logistic regression.
results: Following Bonferroni correction, NEO concentrations were found to be greater in CSF and TRP concentration was found to be lower in the 
plasma of HIV+ versus HIV− individuals, including a subgroup of aviremic (defined as HIV-1 RNA ,50 cps/mL) HIV+ participants receiving antiret-
roviral therapy (n = 44). There was a nonsignificant trend toward higher KYN/TRP ratios in plasma in the HIV+ group (P = 0.027; Bonferroni corrected 
α = 0.0027). In a logistic regression model, lower KYN/TRP ratios in plasma were associated with CI and MDD in the overall HIV+ group (P = 0.038 and 
P = 0.063, respectively) and the aviremic subgroup (P = 0.066 and P = 0.027, respectively), though this observation was not statistically significant following 
Bonferroni correction (Bonferroni corrected α = 0.0031).
cOnclusIOns: We observed a trend toward lower KYN/TRP ratios in aviremic HIV+ patients with CI and MDD.
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implicating indirect pathways for neuronal injury and 
death.20,21 This might be accomplished by the inherent tox-
icity of viral proteins and the release of inflammatory media-
tors and neurotoxins by infected or activated macrophages 
and microglia.20,21
The role of tryptophan (TRP), the effects exerted by its 
catabolites on neural tissue, and the consequences for mood 
and cognition in PLWH are areas of increasing interest. TRP 
acts as a substrate of the tetrahydrobiopterin (BH4)-dependent 
tryptophan-hydroxylase (TPH), leading to the production of 
5-hydroxytryptamine (serotonin). TRP can also be catabo-
lized by the heme-dependent enzymes, TRP 2,3-dioxygenase 
(TDO) and indoleamine 2,3-dioxygenase (IDO-1; Fig. 1), 
ultimately resulting in the production of kynurenine (KYN) 
and its derivatives.22–24
Under physiological conditions, TRP degradation occurs 
primarily in the liver, mediated by TDO, which is activated 
when the concentration of TRP exceeds the requirements 
for its metabolic needs. In contrast, IDO-1 is responsible for 
extrahepatic TRP degradation and is inducible by proinflam-
matory cytokines.25,26
In the brain, the cellular localization of the KYN pathway 
has been shown to be primarily in infiltrating macrophages 
and resident microglial cells.23,27 Increasing TRP degrada-
tion via the IDO-1 pathway diverts it away from serotonin 
production and results in the production of several neuroactive 
intermediates, some of which can be either neurotoxic, such 
as 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid 
(3-HAA), and quinolinic acid (QUIN), or neuroprotective, 
such as kynurenic acid (KYNA) and picolinic acid (PIC).22,23,27–
29 The net result during HIV infection is, as yet, unknown, but 
there is potential for neural damage to occur.30–34
Prevous studies have compared TRP metabolism to 
mood disturbance and CI in HIV+ individuals, but most of 
these were performed in small, heterogeneous samples and 
used plasma samples alone.35–41 In a recent retrospective cross-
sectional analysis of cerebrospinal fluid (CSF) samples from 
HIV+ individuals, Grill et al.42 reported untreated HIV− 
infection to be associated with increased CNS IDO-1 activ-
ity compared to treated individuals, as reflected by elevated 
KYN-to-TRP (KYN/TRP) ratios. In patients with acute 
HIV infection, increased KYN/TRP ratios were associated 
Inflammatory
factors
(eg, IFN-γ
TNF-α) 
huMφ/DC 
Tryptophan 
IDO + 
Kynurenine 
3-Hydroxykynurenine 
3-Hydroxyanthranilic acid 
2-amino-3-
carboxymuconate-
semialdehyde 
Kynurenic acid 
Serotonin 
5-hydroxytryptophan 
− 
BH4 
L-DOPA 
Dopamine 
Tyrosine 
Phenylalanine - - 
− 
Picolinic acid Quinolinic acid NAD+ 
+ 
ROS 
+ 
−
NH2PPP Neopterin + 
PAH TPH 
GTP-CH1 + 
figure 1. Effects of inflammatory factors on indoleamine 2,3-dioxygenase (IDO-1) and guanosine-triphosphate-cyclohydrolase-1 (GTP-CH1) 
pathways.22,23,29,30
notes: reprinted from capuron et al29, with permission from elsevier. “+” indicates upregulated; “−” indicates downregulated.
Abbreviations: Ifn-γ, interferon gamma; tnf-α, tumor necrosis factor-alpha; huMφ/Dc, human monocytes and dendritic cells; Gtp-ch1, guanosiine-
triphosphate-cyclohyrdolase-1; nh2ppp, 7,8-dihydroneopterin triphosphate; Bh4, tetrahydropbiopterin; pah, phenylalanine-hydroxylase; tph, 
tryptophan-hydroxylase; l-Dopa, l-3,4-dihydroxyphenylalanine; ros, reactive oxygen species; naD+, nicotinamide adenine dinucleotide. 
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with increased depressive symptoms. In addition, patients 
with more severe CI displayed a markedly elevated phenylala-
nine (PHE)/tyrosine (TYR) ratio.
The aim of our study was to determine if chronic immune 
activation in HIV+ individuals, as estimated by concentra-
tions of inflammatory biomarkers (IFN-γ, tumor necrosis 
factor-alpha [TNF-α], NEO), is associated with increased 
TRP metabolism via the KYN pathway (as measured by the 
KYN/TRP ratio),41,43,44 resulting in depressed mood and 
CI. We also explored the role of phenylalanine-hydroxylase 
(PAH) activity (as measured by the phenylalanine-to-tyrosine 
[PHE/TYR] ratio).
Methods
study design. We performed a cross-sectional analysis of 
archived CSF and plasma samples collected from HIV+ and 
HIV− individuals. Because this study analyzed de-identified, 
archived samples, it was exempt from seeking ethics commit-
tee approval.
Patient selection. Study participants with MDD and 
CI, as well as comparable unaffected comparison groups, 
were selected from the University of California, San Diego’s 
(UCSD) HIV Neurobehavioral Research Center-based proj-
ects, which had already been reviewed and approved by the 
UCSD’s Human Subjects Protection Program.16,45
Eligible participants were adults who were tested as 
either positive or negative for HIV-1 antibody, with or without 
CI and/or MDD. HIV+ individuals and HIV− controls were 
matched for gender only. Specific exclusion criteria included 
a history of MDD, acute HIV infection, active opportunistic 
infection, history of head trauma associated with neurologi-
cal complications, and those older than 50 years (older age is 
associated with lower TRP levels).
study procedures. All participants received a com-
prehensive medical examination, which included an assess-
ment of HIV disease (eg, current and nadir CD4+ cell 
count, and HIV-1 RNA in CSF and plasma) and ART 
characteristics, in addition to a comprehensive psychi-
atric and neuropsychological evaluation. Diagnostic and 
Statistical Manual, Fourth Edition (DSM-IV)46 diagnoses 
for current and lifetime MDD were determined using the 
Composite International Diagnostic Interview (CIDI).47 
Cognitive performance was determined with a comprehen-
sive battery of tests covering seven ability domains (learn-
ing, memory, attention/working memory, verbal fluency, 
processing speed, executive functioning, and motor speed). 
Raw test scores were converted into demographically 
adjusted T-scores and used to derive domain and global 
deficit scores (GDS), ranging from 0 (no impairment) to 5 
(severe impairment).48 A GDS greater than or equal to 0.5 
was used to classify CI.12,49 All staff administering these 
tests were certified according to standardized procedures at 
their entry into the workforce and periodically recertified. 
No deviations were detected in testing for MDD or CI. 
Whilst conducting this research, the study team has 
complied with the ethical principles for medical research 
involving human subjects as defined by the World Medical 
Associations’ Declaration of Helsinki.
laboratory procedures. Plasma and CSF concentra-
tions of TRP, KYN, PHE, and TYR were measured by 
high-performance liquid chromatography (HPLC) by two 
methods using the ProStar 210 solvent delivery system (Agilent 
Technologies Inc.). Sample injection was controlled by a 
ProStar 400 autosampler, a ProStar 360 fluorescence detector, 
and a ProStar 325 ultraviolet detector (Agilent). Separation 
was accomplished at room temperature using a reversed-
phase LiChroCART 55-4 mm cartridge (Merck), filled with 
Purospher STAR RP-18 (3 µm grain size; Merck) together 
with a reversed-phase C18 precolumn (Merck). Before HPLC, 
serum protein was precipitated with 0.015 mM trichloroacetic 
acid. For both measurements, l-nitro-tyrosine is used as an 
internal standard and monitored at the 360 nm wavelength.
TRP and KYN concentrations were measured in one 
chromatographic run using dihydrogen phosphate solution for 
separation on reversed-phase C18 material with mobile phase 
0.015 M sodium acetate/acetic acid (pH = 4) + 5% methanol 
and with the fluorescence detector set at 285 nm excitation and 
360 nm emission wavelengths. Ultraviolet (UV) absorption to 
detect KYN and l-nitro-tyrosine concentrations was measured 
at the 360 nm wavelength.50,51 For PHE and TYR measure-
ments, the mobile phase was aqueous 15 mM KH2PO4, at a 
flow rate of 0.9 mL/minute, with the fluorescence detector set at 
210 nm excitation and 302 emission wavelengths.52 UV absorp-
tion to detect l-nitro-tyrosine concentrations was measured at 
the 360 nm wavelength (see above). Within-run and between-
run coefficients of variance (CVs) are all ,5% for all analytes.
The ratios of KYN/TRP and PHE/TYR were calculated 
as indexes of IDO-1 and PAH activity, respectively.
Neopterin (NEO) concentrations were measured by 
enzyme-linked immunosorbent assay (BRAHMS Diagnostics) 
following the manufacturer’s protocol (sensitivity, 2 nmol/L).
To estimate the production of nitrous oxide (NO), the 
stable NO metabolite nitrite (NO2−) was determined in the 
cell-free culture supernatants using the Griess reaction assay 
(Promega),53,54 where sulfanilamide was quantitatively con-
verted to a diazonium salt on reaction with NO2− in the pres-
ence of phosphoric acid. The diazonium salt was then coupled 
to N(1-naphthyl)ethylenediamine dihydrochloride, forming 
an azo dye that was read at 540 nm in a spectrophotometer 
and calculated by external standardization.
IFN-γ and TNF-α were quantified using the commer-
cially available Human TNF-alpha Quantikine ELISA Kit 
(DTA00C; sensitivity, 5.5 pg/mL) and the Human IFN-
gamma Quantikine ELISA (DIF50; sensitivity, 8 pg/mL), 
respectively (both from R&D Systems), using the manufac-
turer’s protocol. The majority of IFN-γ samples obtained were 
below the detection limit, and so, this parameter was excluded 
from further analyses.
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statistical methods. Statistical analyses were performed 
with IBM’s SPSS Software Version 21. The results were sub-
jected to tests of the normal distribution. Nonparametric tests 
were selected for use due to skewed distributions in the data. 
Univariate analyses were conducted using Mann–Whitney 
U tests and chi-square tests for independence to look for dif-
ferences in baseline characteristics between the HIV+ and 
HIV− groups, and between the HIV+ individuals receiv-
ing ART and those not receiving ART. Comparisons of the 
biochemical and immunological markers in CSF and plasma 
between the HIV+ and HIV− groups, and between the sub-
group of HIV+ individuals who were taking virologically sup-
pressive ART (n = 44) and the HIV− group were made using 
Mann–Whitney U tests. Initially, the alpha for the Mann–
Whitney U tests was set at 0.05 as these were exploratory 
analyses. Bonferroni adjusted alpha values of 0.0027 per test 
(0.05/18) were also applied.
Multivariate linear regression analysis explores the 
relationship between TNF-α and NEO with the clinically 
relevant covariates such as HIV-1 RNA in CSF and plasma 
(# or .50 cps/mL), current CD4+ cell count, and ART-use. 
In order to understand whether an association exists between 
the inflammatory biomarkers and TRP metabolism, the rela-
tionship between TNF-α and NEO and the KYN/TRP ratio 
in CSF and plasma from HIV+ individuals was analyzed in a 
second multivariate model.
To compare TRP metabolism via the KYN pathway 
with neuropsychiatric outcomes, logistic regression analy-
ses were performed for the KYN/TRP ratio in both CSF 
and plasma and either binary MDD or CI status. Due to 
the number of comparisons performed, Bonferroni adjusted 
alpha values of 0.0031 per test (0.05/16) were applied to the 
final multivariate analyses exploring the depressive and cog-
nitive parameters.
In order to account for the potential confounding 
effects of the use of antidepressant agents in some patients, 
Mann–Whitney U tests were performed to determine 
whether there was a correlation between the use of antide-
pressant medication and TRP, KYN, and the KYN/TRP 
ratio. These were performed for the overall HIV+ group, 
as well as for patients with HIV-1 RNA .50 cps/mL or 
,50 cps/mL in both CSF and plasma. 
results
baseline characteristics. The baseline characteristics of 
the 157 participants (HIV+ = 91 and HIV− = 66) are listed 
in Table 1. Of the 91 HIV+ patients, 65 were receiving ART 
(information on the regimens used was available for 44 of 65 
patients). Those on ART had lower nadir CD4+ cell counts 
(144 vs. 330 cells/µL). In the HIV+ group, the median cur-
rent CD4+ count was 421 cells, reflecting substantial immune 
recovery on ART. HIV+ participants had higher rates of CI 
(39% vs. 14%), MDD (46% vs. 15%), and current antidepres-
sant use (serotonin reuptake inhibitors, including both tricyclic 
antidepressants and selective serotonin reuptake inhibitors; 
30% vs. 3%) compared to HIV− participants. The CSF and 
plasma samples were collected from patients between 1991 
and 2009 and subsequently stored at −80 °C.
univariate analysis of biochemical and immunologi-
cal markers. The concentrations of each of the biochemical 
and immunological markers in both plasma and CSF are pre-
sented in Table 2.
Significantly higher concentrations of TNF-α were 
observed in the CSF of both the overall HIV+ group 
(P , 0.001; α = 0.0027) and the ART-treated aviremic 
(,50 cps/mL HIV-1 RNA) subgroup (P = 0.008; α = 0.0027) 
compared with HIV− controls, though the subgroup 
comparison did not remain a significant post-Bonferroni cor-
rection. No differences were observed in plasma concentra-
tions of TNF-α in either group.
Higher concentrations of NEO were observed in both 
the CSF and plasma of the HIV+ group (P , 0.001 and 
P = 0.02, respectively; α = 0.0027) and in the CSF of the 
aviremic subgroup (P = 0.002; α = 0.0027) compared with 
controls. Again, the observed difference in plasma was not 
statistically significant after Bonferroni correction.
Higher concentrations of nitrite were observed in the 
plasma, but not CSF, of both the overall HIV+ group (P = 0.010; 
α = 0.0027) and the aviremic subgroup (P = 0.036; α = 0.0027) 
compared with controls, though neither observation remained 
significant following the Bonferroni correction.
Lower concentrations of TRP were observed in both 
the CSF and plasma of the HIV+ group (P = 0.012 and 
P , 0.001, respectively; α = 0.0027) and in the plasma of 
the aviremic subgroup (P = 0.004; α = 0.0027) compared 
with controls. No significant differences were observed for 
KYN. HIV+ participants had greater KYN/TRP ratios in 
plasma than HIV− controls (P = 0.027; α = 0.0027). Only 
the difference in TRP concentration between the HIV+ and 
HIV− groups in plasma remained significant following the 
Bonferroni correction.
Concentrations of either PHE or TYR did not differ 
between any of the groups. A significantly elevated PHE/
TYR ratio was observed in the CSF of the HIV+ group com-
pared with controls (P = 0.038; α = 0.0027), though this was 
not significant following Bonferroni correction. There were no 
significant differences observed in plasma or in the CSF and 
plasma of the aviremic subgroup.
Multivariate analyses. In the first model, viremia and 
ART use positively correlated with TNF-α and NEO con-
centrations in CSF, while lower current CD4+ cell counts 
were associated with higher concentrations of these mark-
ers. Viremia and current CD4+ cell count were the strongest 
predictors of TNF-α and NEO. Nadir CD4+ cell count was 
also included as a covariate in the model but was not found 
to be significantly correlated with either marker. The models 
evaluating TNF-α and NEO in plasma were not statisti-
cally significant.
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Table 1. Demographic and disease characteristics.
HIV+ HIV- P VAluE HIV+ on ART HIV+ noT on ART P VAluE
n 91 66 – 65 26 –
Age, yrs, Median (IQR) 40 (34,44) 35 (28,44) 0.027 40 (36,44) 37 (32,42) 0.085
gender, Male 80 (88%) 61 (92%) 0.512 56 (86%) 24 (92%) 0.647
Ethnicity
White 47 (52%) 36 (55%) 0.352 33 (51%) 14 (54%) 0.810
Black 21 (23%) 13 (20%) 14 (22%) 7 (27%)
asian 1 (1%) 2 (3%) 1 (2%) 0 (0%)
hispanic 20 (22%) 10 (15%) 15 (23%) 5 (19%)
other 2 (2%) 5 (8%) 2 (3%) 0 (0%)
Current CD4 cells/ul,  
Median (IQR)a
421 (251,594) 820 (670,989) ,0.001 435 (219,609) 402 (263,510) 0.667
nadir CD4 cells/ul,  
Median (IQR)
191 (35,300) – – 144 (23,222) 330 (200,450) ,0.001
HCV+b 5 (6%) 9 (17%) 0.102 3 (5%) 2 (3%) 0.979
gDS $0.5c 35 (39%) 9 (14%) 0.002 28 (44%) 7 (28%) 0.260
MDD 42 (46%) 10 (15%) ,0.001 27 (42%) 15 (58%) 0.163
Antidepressant use  
everd 25 (32%) 12 (21%) 0.240 15 (27%) 10 (43) 0.237
currente 27 (30%) 2 (3%) ,0.001 21 (32%) 6 (23%) 0.537
Current ARV regimenf – – – – –
nrtI(s) in regimen 40 (91%)
nnrtI-based 14 (32%)
pI-based 20 (45%)
nrtI-based 5 (11%)
other 5 (11%)
HIV-1-RnA in plasma
Median HIV-1-RnA
(IQR)h
– – – ,50 (0,393) 18,350 (7293,66600) ,0.001
hIV-1-rnag – – – 
#50 cps/ml n = 40 n = 0 – 
.50 cps/ml n = 22 n = 25 –
HIV-1- RnA in CSf
Median HIV-1-RnA
(IQR)h
– – – ,50 (0,6) 315 (73,1220) ,0.001
hIV-1-rnah
,50 cps/ml n = 44 n = 5 – 
.50 cps/ml n = 6 n = 16
notes: ahIV+, n = 88; hIV−, n = 64; on art, n = 63; not on art, n = 25.bhIV+, n = 78; hIV−, n = 53; on art, n = 55; not on art, n = 23. chIV+, n = 89; hIV−, n = 63; 
on art, n = 64; not on art, n = 25.dhIV+, n = 79; hIV−, n = 57; on art, n = 56; not on art, n = 23. ehIV+, n = 91; hIV−, n = 65; on art, n = 65; not on art, n = 26.
farV regimen information only available for n = 44. gon art, n = 62; not on art, n = 25.hon art, n = 50; not on art, n = 21.
Abbreviations: GDS, global deficit score; ART, antiretroviral therapy; CSF, cerebrospinal fluid; IQR, interquartile range.
In the second model investigating the relationship 
between the inflammatory markers and the KYN/TRP ratio, 
levels of TNF-α and NEO positively correlated with the 
KYN/TRP ratio in both CSF (R2 = 0.277; analysis of variance 
[ANOVA], P = 0.008) and plasma (R2 = 0.674; ANOVA, 
P , 0.001) outcomes. There were no significant correlations 
for any of the groups in CSF for either MDD or CI status 
(data not shown). However, in plasma, a lower KYN/TRP 
ratio was weakly associated with MDD in the HIV+ group, 
although this was not statistically significant (χ2 = 3.458 
[1, n = 84], B = −1.643, P = 0.063; α = 0.0031). Stratification 
by binary viremia status identified that this trend was driven 
by the aviremic subgroup (χ2 = 4.874 [1, n = 32], B = −4.054, 
P = 0.027; α = 0.0031; Fig. 2A), though this was not significant 
following Bonferroni correction.
A similar association was observed for the KYN/TRP 
ratio in plasma and CI. Following Bonferroni correction, 
nonsignificant negative correlation trends were observed in 
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Table 2. univariate analysis – biochemical and immunological parameters in csf and plasma, hIV+ individuals and hIV+ individuals with hIV-1 
rna ,50 cps/ml vs. hIV-controls.
n HIV-(ToTAl n = 66) n HIV+ (ToTAl n = 91) HIV+ VS 
HIV- 
P-VAluE
n HIV+, ,50 cps/ml) 
(ToTAl n = 44)
HIV+, 
,50 cps/ml 
VS HIV-
P-VAluE
MEDIAn (IQR) MEDIAn (IQR) MEDIAn (IQR)
CSf
Tnf-α (µmol/mmol) 19 3.84 (3.59,4.47) 33 6.40 (4.92,7.18) ,0.001 21 5.43 (3.85,6.71) 0.008
neopterin (µmol/mmol) 43 4.30 (3.77,4.65) 65 5.15 (4.41,9.23) ,0.001 42 4.90 (4.26,6.26) 0.002
Tryptophan (µmol/mmol) 43 1.98 (1.58,2.52) 63 1.66 (1.21,2.05) 0.012 41 1.72 (1.29,2.09) 0.076
Kynurenine (µmol/mmol) 43 0.24 (0.09,0.27) 63 0.13 (0.09,0.27) 0.621 41 0.10 (0.09,0.27) 0.536
Kynurenine-to-tryptophan ratio 
(µmol/mmol/µmol/mmol)
43 76.72 (44.20,151.17) 63 101.77 (54.19,165.21) 0.262 41 90.80 (51.92,151.90) 0.516
Tyrosine (µmol/mmol) 24 9.20 (7.77,13.32) 28 9.05 (6.80,11.14) 0.229 18 9.05 (7.01,11.41) 0.315
Phenylalanine (µmol/mmol) 24 8.68 (6.61,10.16) 28 9.17 (7.68,13.08) 0.174 18 9.17 (7.64,13.89) 0.195
Phenylalanine-to-tyrosine ratio 
(µmol/mmol/µmol/mmol)
24 0.77 (0.66,1.09) 28 0.96 (0.78,1.29) 0.038 18 0.95 (0.74,1.31) 0.089
nitrite (µmol/mmol) 13 0.40 (0.10,1.50) 11 1.00(0.40,1.20) 0.393 7 1.00 (0.40,1.20) 0.420
Plasma
Tnf-α (µmol/mmol) 19 7.77 (6.16,10.41) 28 7.75 (4.72,10.39) 0.948 12 5.40 (3.49,8.13) 0.057
neopterin (µmol/mmol) 66 5.65 (4.76,8.60) 84 9.27 (4.98,15.64) 0.020 32 7.60 (4.62,14.30) 0.265
Tryptophan (µmol/mmol) 66 55.39 (46.04,66.08) 84 45.85 (38.38,54.32) ,0.001 32 47.06 (40.41,55.28) 0.004
Kynurenine (µmol/mmol) 66 2.08 (1.52,2.53) 84 2.07 (1.61,2.66) 0.791 32 1.88 (1.32,2.55) 0.625
Kynurenine-to-tryptophan ratio 
(µmol/mmol/µmol/mmol)
66 37.56 (26.36,53.34) 84 47.49 (30.51,61.42) 0.027 32 41.37 (28.24,53.59) 0.413
Tyrosine (µmol/mmol) 47 49.15 (42.76,64.72) 55 46.80 (38.99,58.18) 0.200 20 49.07 (42.56,61.56) 0.902
Phenylalanine (µmol/mmol) 47 66.94 (56.42,85.87) 55 65.49 (56.52,88.95) 0.928 20 73.82 (54.11,92.53) 0.468
nitrite (µmol/mmol) 47 16.86 (12.09,28.24) 55 25.30 (16.68,35.58) 0.010 20 26.49 (20.55,33.89) 0.036
notes: Mann–Whitney U test was performed. Values are represented as median (IQR) unless otherwise noted.
Abbreviations: Ifn-γ, interferon gamma; tnf-α, tumor necrosis factor-alpha; IQR, interquartile range.
the overall HIV+ group (χ2 = 4.312 [1, n = 82], B = −1.926, 
P = 0.038; α = 0.0031) and the aviremic subgroup (χ2 = 3.388 
[1, n = 32], B = −3.078, P = 0.066; α = 0.0031).
Significant correlations were not observed for either the 
viremic subgroup or the HIV− controls (Fig. 2).
The logistic regression analyses described above were also 
performed using the PHE/TYR ratio in CSF and plasma as the 
predictor variable. No significant associations were observed 
(for all comparisons, P . 0.05 before Bonferroni correction).
In the models evaluating the effects of antidepressant 
drugs on TRP, KYN, and the KYN/TRP ratios, lower KYN 
concentrations (Z = −2.645; P = 0.008; r = 0.289; n = 84) and 
KYN/TRP ratios (Z = 1.984; P = 0.047; r = 0.216; n = 84) 
in plasma were significantly associated with the use of antide-
pressants in the overall HIV+ group. This association was not 
observed in either of the subgroups in plasma or in any of the 
groups in CSF. Multivariate analyses were also performed to 
explore the relationship between the KYN/TRP ratio in both 
CSF and plasma and clinically relevant covariates (viremia in 
plasma and CSF, current and nadir CD4 count, ART use and 
current antidepressant use). Neither of these models were found 
to be statistically significant overall, though there was a trend 
toward significance for the model investigating KYN/TRP in 
plasma (R2 = 0.190; ANOVA, P = 0.058). In this model, anti-
depressant use was statistically significantly associated with 
lower KYN/TRP ratios (Correlation = −0.259; P = 0.009).
discussion
In this study, PLWH had greater concentrations of TNF-α 
and NEO in CSF and had lower concentrations of TRP in 
plasma compared to HIV− controls. The changes observed 
in NEO and TRP persisted in virologically suppressed 
patients receiving ART. We observed a trend toward lower 
KYN/TRP ratios in patients with CI and MDD in plasma 
in both the overall HIV+ group and an aviremic subgroup; 
however, these findings were not statistically significant. 
This trend was not observed in HIV+ participants with 
detectable viral loads.
The increases in TNF-α and NEO were expected, which 
support the observations made in previous studies, indicating 
increased ongoing monocyte, macrophage and microglial acti-
vation, and correlating positively with IDO-1 activity.41,55–63
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In the study by Grill et al.42, only untreated acute HIV 
infection was associated with an increase in the KYN/
TRP ratio, which was associated with increased depres-
sive symptoms. Treated HIV infection was not found to be 
associated with an increase in the KYN/TRP ratio, or with 
CI or MDD. In contrast, our observations do not support 
this and, instead, suggest that there may be a subpopulation 
of aviremic ART-treated patients who have low KYN/TRP 
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figure 2. the K/t ratio in plasma and its relationship with MDD (A) and cI (b).
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ratios and are experiencing CI and MDD. Our data suggest 
that the KYN pathway may protect against CI and MDD 
in aviremic patients. The reasons for this are, as yet, unclear. 
Interestingly, differences in the KYN/TRP ratio were not 
observed in HIV− subjects suffering from MDD or CI com-
pared to those without symptoms, indicating that other fac-
tors are involved in psychiatric disease in these subjects.
TRP degradation along the KYN pathway results in the 
synthesis of neuroactive metabolites – 3-HK with neurotoxic, QUIN 
with excitatory, and KYNA with inhibitory properties.64–68
Greater CSF QUIN concentrations correlate with the 
severity of CI in PLWH.66,69–71 CSF QUIN levels have been 
shown to fall rapidly with ART,59,67,70–72 probably as a result 
of a reduction in virus-related immune activation and a reduc-
tion in the activity of IDO-1.73
KYNA is known to be neuroprotective due to its ability to 
block excitotoxic neuronal damage74,75 and has been shown to 
be elevated in the brains of HIV-1 patients.64 In our study, we 
observed that the aviremic patients with CI and MDD had lower 
KYN/TRP ratios from those not suffering from these condi-
tions, suggesting that higher KYN/TRP ratios may potentially 
have a protective effect. It is tempting to speculate that this phe-
nomenon is due to an increase in either KYNA concentration or 
activity; a hypothesis that should be further investigated.
We also observed a trend toward increases in the PHE/
TYR ratio in CSF, indicating a reduction in the production of 
dopamine and its downstream catabolites. However, in con-
trast to the observations made by Grill et al.42, the differences 
in the PHE/TYR ratio did not correlate with CI or MDD in 
our study population.
An important limitation of our analyses is that they did 
not account for serotonin production. Serotonin can be unstable 
and prone to oxidation, which can contribute to preanalytical 
errors. However, lowered serotonin concentrations have been 
described in the blood and CSF of patients with HIV-1 infec-
tion.76,77 In support of this, many HIV+ patients with depres-
sion respond well to treatment with SSRIs, indicating that, in 
some patients, low serotonin levels may be the primary cause 
of depression. This is consistent with the hypothesis that low 
serotonin production could be due to immune-mediated TRP 
depletion.78 In this study, antidepressant use was significantly 
greater in HIV+ patients compared with HIV− controls. We 
found that antidepressant use was associated with both lower 
KYN concentrations and KYN/TRP ratios in plasma in the 
overall HIV+ group. In contrast to this, in a previous study by 
Schroecksnadel et al and in the previous work by our group 
(unpublished data), no differences were observed in either TRP 
or KYN concentrations in depressed HIV+ individuals who 
were treated with antidepressants compared with those not 
treated.39 However, in light of the findings from this study, our 
results should be interpreted with caution as antidepressant use 
could be a significant confounder.
Our study has several other important limitations. First, 
the HIV+ group was heterogeneous in terms of virological 
and immunological status, as well as ART use and the types 
of treatment used. ART can induce declines in CSF NEO 
and KYN/TRP ratio levels.73 However, the impact, if any, of 
differences between different treatments on TRP metabolism 
has yet to be explored.
Second, the study population is derived from a diverse 
mix of ethnicities. There are six reported IDO-1 genetic 
transcript variants, the frequencies of which have been 
assessed in European, Chinese, Japanese, and African 
cohorts.79 Genetic variations in one or more of these genes, 
or other genes in the KYN pathway, could account for vari-
able susceptibility to disease or disease outcomes. However, 
these have not yet been fully examined in the scientific lit-
erature and so their effect, if any, is as yet unknown.79 Also, 
the potential contribution of dietary differences to TRP levels 
could not be assessed in our study.80
The observed results should be interpreted with caution 
due to the cross-sectional study design. IDO-1 activity is not 
consistent over time, and so the observed values and asso-
ciations only provide a snapshot. Additional studies, which 
include longitudinal follow-up, may be required to further 
elucidate the role of TRP catabolism and associated metabolic 
pathways in HIV-1-associated neurological complications.81
Given the exploratory nature of this pilot study, we ini-
tially chose not to correct for multiple comparisons in the sta-
tistical analysis so that possible associations were not missed 
due to conservative multiplicity corrections. We did, how-
ever, perform Bonferroni corrections resulting in a number of 
initially significant correlations no longer being significant. 
The Bonferroni correction is a conservative method when 
there are a large number of comparisons to account for, as in 
this case. Therefore, we need to acknowledge the possibility 
of type II statistical errors when evaluating these data.
While we excluded patients with active opportunistic 
infections and a history of head trauma associated with neuro-
logical complications, and collected information on the rates 
of HCV, MDD, and methadone use in our study population, 
we did not collect information on other comorbidities, such as 
metabolic disorders and vascular disease, which are associated 
with CI. Our observations could be confounded by the effects 
of other unknown comorbidities.
The severity of CI among HIV+ individuals was mostly 
mild. As a result, our findings may not generalize to more 
severely affected patients. Few patients met the criteria for 
HIV-associated dementia in our sample, which is consistent 
with the current rates of HIV-associated neurocognitive dis-
order (HAND) diagnoses.
In summary, we observed a trend toward lower KYN/
TRP ratios in patients with CI and MDD in plasma in both 
the overall HIV+ group and an aviremic subgroup; however, 
these findings were not statistically significant. One may 
hypothesize that the net result of the KYN/TRP ratio in 
ART-treated, virologically suppressed patients may be neu-
roprotective in some cases. The causes of CI and MDD in 
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HIV+ individuals are likely to be multifactorial, and these 
findings warrant further exploration.
Further work is required in less heterogeneous groups 
with longitudinal follow-up. The effect, if any, of ART drugs, 
diet, and lifestyle on the KYN pathway needs to be char-
acterized in HIV patients. Additional work should include 
measurement of serotonin and a more complete analysis of 
KYN catabolites.
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